1227268-74-7 Usage
General Description
1-(Phenylsulfonyl)-5-broMo-4-azaindole is a chemical compound that belongs to the class of azaindoles. It is a derivative of indole with a bromine substituent and a phenylsulfonyl group attached to the nitrogen atom. 1-(Phenylsulfonyl)-5-broMo-4-azaindole is of interest in medicinal chemistry due to its potential biological activities. The phenylsulfonyl group is often used as a pharmacophore in drug design, and the bromine substituent may play a role in modulating the compound's interactions with biological targets. 1-(Phenylsulfonyl)-5-broMo-4-azaindole may have applications in the development of new pharmaceuticals and agrochemicals due to its structural features and potential biological activities. Further research is needed to fully understand its properties and potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 1227268-74-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,7,2,6 and 8 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1227268-74:
(9*1)+(8*2)+(7*2)+(6*7)+(5*2)+(4*6)+(3*8)+(2*7)+(1*4)=157
157 % 10 = 7
So 1227268-74-7 is a valid CAS Registry Number.
1227268-74-7Relevant articles and documents
NEW ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME
-
Paragraph 0142-0144, (2020/02/28)
Provided in the present invention are an organic electroluminescent compound represented by chemical formula 1 and chemical formula 2, and an organic electroluminescent device comprising the same. [Chemical formula 1] [Chemical formula 2] The organic elec
4-AZAINDOLE DERIVATIVES
-
Page/Page column 59; 60, (2015/04/22)
4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
